|
|
Post by yossarian on Mar 14, 2016 16:45:26 GMT -5
Listened to conference call - significant items.
1. Afrezza back from Sanofi April 5 though there may be some loose ends.
2. Implication pretty clear Mannkind has no plans to spend more on marketing than Sanofi.
3. Don't currently anticipate using $30 million credit facility from the Mann Group
4. Still no clear timelines for any specific actions. Mannkind did not commit to anything prior to April 5 handoff from Sanofi.
Still a lot of basically "trust us" from Matt
|
|
|
|
Post by cjc04 on Mar 14, 2016 16:55:53 GMT -5
IMO, a non event, which I think we all expected.
I think The CCO appointment was a positive, and shows they're not planning for BK.
And my personal favorite moment was Matt's exchange with Olsen. Nice job Matt, made him sound stupid!
|
|
|
|
Post by lakers on Mar 14, 2016 16:56:56 GMT -5
|
|
|
|
Post by peppy on Mar 14, 2016 16:57:01 GMT -5
Listened to conference call - significant items. 1. Afrezza back from Sanofi April 5 though there may be some loose ends. 2. Implication pretty clear Mannkind has no plans to spend more on marketing than Sanofi. 3. Don't currently anticipate using $30 million credit facility from the Mann Group 4. Still no clear timelines for any specific actions. Mannkind did not commit to anything prior to April 5 handoff from Sanofi. Still a lot of basically "trust us" from Matt that's where we are, trust us. we are at trust us with a patent portfolio who's time has come and an approved FDA drug. A licensing agreement. he can not sell it until after sanofi insulin is sold, or it has to be repackaged. his hands are so tied. Receptor is private, and it likes it that way.
We have a commercial officer. Marketing and sales. plan on.
|
|
|
|
Post by nylefty on Mar 14, 2016 16:58:10 GMT -5
Listened to conference call - significant items. 1. Afrezza back from Sanofi April 5 though there may be some loose ends. 2. Implication pretty clear Mannkind has no plans to spend more on marketing than Sanofi. 3. Don't currently anticipate using $30 million credit facility from the Mann Group 4. Still no clear timelines for any specific actions. Mannkind did not commit to anything prior to April 5 handoff from Sanofi. Still a lot of basically "trust us" from Matt Number 2 wasn't "pretty clear" to me. Why do you think it was? Number 3 somewhat encouraging. |
|
|
|
Post by nemzter on Mar 14, 2016 17:01:26 GMT -5
Hmm, wish they had Dr Urbanski talk about the trial abstracts...
|
|
|
|
Post by tchalaa on Mar 14, 2016 17:02:34 GMT -5
|
|
|
|
Post by sccrbrg on Mar 14, 2016 17:03:16 GMT -5
They cannot discuss the abstracts until the conference.
|
|
|
|
Post by oldfishtowner on Mar 14, 2016 17:20:35 GMT -5
Or maybe 1 or more non-US partnerships to be signed on April 5? |
|
|
|
Post by peppy on Mar 14, 2016 17:31:06 GMT -5
The net loss for 2015 was $368.4 million, including total non-cash impairment charges of $206.6 million, or $0.91 per share based on 406.2 million weighted average shares outstanding, higher than the net loss of $198.4 million, or $0.51 per share on 385.2 million weighted average shares outstanding in 2014. The number of common shares outstanding at December 31, 2015 was 428.7 million. Cash and cash equivalents at December 31, 2015 were $59.1 million, compared to $32.9 million in the third quarter of 2015. During the fourth quarter of 2015, we received $34.7 million in net proceeds from sale of stock on the Tel Aviv Stock Exchange, $0.7 million in proceeds from warrants and options exercised, $2.6 million in payments from Sanofi for product shipments, and $13.6 million in net proceeds from the sale of stock pursuant to our at-the-market sales facility. Currently, $30.1 million remains available to borrow under our amended loan arrangement with The Mann Group. - See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=960565#sthash.SkqT2qcZ.dpuf |
|
|
|
Post by alethea on Mar 14, 2016 17:33:26 GMT -5
IMO, a non event, which I think we all expected. I think The CCO appointment was a positive, and shows they're not planning for BK. And my personal favorite moment was Matt's exchange with Olsen. Nice job Matt, made him sound stupid!Here here! Ten thumbs up! I thought Matt stood up strong to that bully Jay Olson. It was like Matt was tired of being pushed around and smacked Olson right in the nose. And Olson sounded a bit like a cowardly, surprised bully often does upon being called out. Is it possible that Olson, one of the lead minions of the cabal of crooks is frustrated by not having complete access to MNKD's plans? Is it possible the crooks won't be able to be so cocksure in their plans to destroy MNKD with their short selling attacks? Will they have to operate without inside information now that Sanofi is out of the picture? Here's to hoping for the utter destruction of this bad actor and his associates. May he reap what he has sown. May Karma deliver to him the Justice he has earned. |
|
|
|
Post by factspls88 on Mar 14, 2016 17:38:18 GMT -5
I thought the lack of questioning by analysts about RLS (or mention by Matt) to be rather odd. Not sure what to make of it.
|
|
|
|
Post by peppy on Mar 14, 2016 18:32:09 GMT -5
They cannot discuss the abstracts until the conference. Matt: "submitted 4 abstracts and all four were accepted. One of those abstracts were selected for our moderated discussion. intend to submit two additional abstracts as late breakers. address the unique pk/pd profile of afrezza and includes the positive outcome of recently completed studies. Data to be presented suggest the pk/pd profile of afrezza is different enough from other current rapid acting insulins as to offer improved efficacy."
June 10 - 14 Late Breaking Abstract Submission Closes March 14, 2016.
|
|
|
|
Post by mnkdfann on Mar 14, 2016 18:33:32 GMT -5
Listened to conference call - significant items. 1. Afrezza back from Sanofi April 5 though there may be some loose ends. 2. Implication pretty clear Mannkind has no plans to spend more on marketing than Sanofi. 3. Don't currently anticipate using $30 million credit facility from the Mann Group 4. Still no clear timelines for any specific actions. Mannkind did not commit to anything prior to April 5 handoff from Sanofi. Still a lot of basically "trust us" from Matt Number 2 wasn't "pretty clear" to me. Why do you think it was? Number 3 somewhat encouraging. Michael E. Castagna said they planned to do "low cost DTC" to people with Type 1 and 2 diabetes. Read into that what you will, I guess. |
|
|
|
Post by anderson on Mar 14, 2016 18:57:33 GMT -5
So the large write down is due to the purchase agreement for insulin with Amphastar since they are contractually obligated to buy the insulin. What is the accounting advantage of doing this, is there some tax advantage?
|
|
